Sign in
Taking peopleNo phase

Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage

Key facts

Who runs it
Tongji Hospital
Where
China51 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
768 people, planned
Started
25 Oct 2025
Expected to end
30 Jun 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Stereotactic thrombolysis with Tenecteplase
Record updated
3 November 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • . Age 18 to 80 years, any gender
  • . Clinically confirmed acute spontaneous supratentorial intracerebral hemorrhage (ICH), with diagnostic CT completed within 24 hours of symptom onset (for patients with unknown time of onset or wake-up stroke, the time from the last known well to symptom detection is used as the presumed onset time)
  • . CT-confirmed supratentorial ICH with hematoma volume calculated by ABC/2 method between 25 mL and 60 mL (inclusive)
  • . National Institutes of Health Stroke Scale (NIHSS) score ≥ 6
  • .Glasgow Coma Scale (GCS) score between 9 and 14 (inclusive)
  • . Pre-stroke modified Rankin Scale (mRS) score ≤ 1
  • . Good compliance, with written informed consent provided by the patient and/or legal guardian, and ability to adhere to the scheduled follow-up visits

Who cannot take part

  • . Myocardial infarction within 30 days prior to randomization
  • .Use of anticoagulants (e.g., warfarin, dabigatran, rivaroxaban, apixaban) within 1 week prior to symptom onset
  • . History of internal bleeding (e.g., gastrointestinal bleeding, genitourinary bleeding, retroperitoneal bleeding) within 3 months prior to randomization
  • . Major surgery or vascular puncture (e.g., venesection, arterial puncture) within 3 months prior to randomization
  • . History of significant head trauma or severe stroke within 3 months prior to randomization
  • . History of intracerebral hemorrhage within 1 year prior to randomization
  • . Patient or family requests craniotomy or neuroendoscopic surgery for hematoma evacuation
  • . Concurrent participation in another investigational drug or device study
  • . History of drug or alcohol abuse/dependence, severe dementia, or psychiatric disorder prior to randomization, anticipated to result in poor compliance and inability to complete follow-up
  • . Brainstem or cerebellar hemorrhage; or thalamic hemorrhage with significant midbrain shift accompanied by third nerve palsy or unreactive dilated pupils
  • . Secondary ICH caused by: head trauma, arteriovenous malformation (AVM), moyamoya disease, intracranial aneurysm, coagulation disorders (hereditary or acquired hemorrhagic diathesis, hemophilia, coagulation factor deficiency, leukemia, etc.), hemorrhagic transformation of cerebral infarction, or tumor; multiple intracranial hemorrhages, subarachnoid hemorrhage (SAH), primary intraventricular hemorrhage, drug-induced hemorrhagic stroke, subdural hemorrhage, epidural hemorrhage
  • . Known high risk of thromboembolism, including: presence of a mechanical heart valve prosthesis, history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. (Note: Atrial fibrillation without mitral stenosis is permitted)
  • . Indications for craniotomy: (1) Progressive impairment of consciousness; (2)Preoperative signs of brain herniation (e.g., foramen magnum herniation, tentorial herniation) posing a life-threatening condition
  • . Intraventricular hemorrhage (IVH) or ICH with rupture into the ventricle causing intraventricular cast formation and/or hydrocephalus anticipated to require external ventricular drainage (EVD)
  • . Known hypersensitivity or intolerance to TNK
  • . Significant abnormalities in the following laboratory parameters:(1)International normalized ratio (INR) > 1.4; any irreversible coagulopathy or known coagulation disorder that cannot be corrected with procoagulants to maintain INR ≤ 1.4. (2) Severe hepatic insufficiency: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3 times the upper limit of normal (ULN). (3) Severe renal insufficiency: estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m². (4)Hemoglobin < 90 g/L.5)Platelet count < 100 × 10⁹/L
  • . History of malignancy, autoimmune diseases (including but not limited to systemic lupus erythematosus, systemic vasculitis), hemorrhagic diathesis (including various hereditary and acquired bleeding disorders), malignant arrhythmias, cardiac insufficiency (B-type natriuretic peptide [BNP] ≥ 1000 pg/mL or left ventricular ejection fraction [LVEF] ≤ 40%), acute myocardial infarction, acute or severe infectious diseases (e.g., intracranial infection, severe pneumonia, sepsis), or any other severe concurrent illness that may exacerbate the condition or interfere with efficacy assessment
  • . Irreversible brainstem dysfunction (bilateral fixed, dilated pupils and decerebrate posturing)
  • . Pre-randomization decision by patient/family for Do-Not-Resuscitate (DNR) or Do-Not-Intubate (DNI) orders regarding life-sustaining measures
  • . Pregnancy (positive urine pregnancy test) in women of childbearing potential

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a phase III prospective, multi-center, open-label, randomized controlled trial (RCT) with blinded endpoint assessment. It plans to enroll 768 subjects with spontaneous supratentorial intracerebral hemorrhage, who will be randomly assigned in a 1:1 ratio to the investigational arm (stereotactic minimally invasive puncture and catheter placement followed by hematoma liquefaction and drainage using tenecteplase, single TNK dose of 0.5mg per time) or the standard medical treatment group.

The 2 groups in the trial

  • MIS+TNKTreatment being tested

    In this group, patients receive standard medical treatment plus mininally invasive stereotactic catheter placement followed by hematoma liquefaction and drainage using tenecteplase (TNK). The single dose of tenecteplase is 0.5mg.

    Treatment: Stereotactic thrombolysis with Tenecteplase

  • Standard medical treatmentNo study treatment, for comparison

    Patients randomized to the control group will receive standard medical management according to the 2022 AHA/ASA Guideline for the Management of Spontaneous Intracerebral Hemorrhage.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07208097, who can take part
Record updated
3 November 2026